Quinapril

Bezeichnung:Quinapril

CAS-Nr85441-61-8

Englisch Name:Quinapril

CBNumberCB1100985

SummenformelC25H30N2O5

Molgewicht438.52

MOL-Datei85441-61-8.mol

Quinapril physikalisch-chemischer Eigenschaften

Schmelzpunkt	120-130°C
Siedepunkt	662.0±55.0 °C(Predicted)
Dichte	1.217±0.06 g/cm3(Predicted)
pka	3.39±0.20(Predicted)
BCS Class	1
CAS Datenbank	85441-61-8(CAS DataBase Reference)

Sicherheit

S-Sätze:

22-24/25

Quinapril Chemische Eigenschaften,Einsatz,Produktion Methoden

S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
Beschreibung
Quinapril is an orally active, non-sulfhydryl ACE inhibitor reportedly useful in the treatment of essential hypertension. The main claimed advantage of quinapril compared with other available ACE inhibitors is its side-effect profile. It is also effective in the management of congestive heart failure.
Originator
Warner-Lambert (USA)
Verwenden
Antihypertensive; enzyme inhibitor (angiotensin-converting).
Definition
ChEBI: Quinapril is a member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a prodrug and an antihypertensive agent. It is a member of isoquinolines, a dicarboxylic acid monoester, an ethyl ester and a tertiary carboxamide.
Trademarks
Accupril (Pfizer); Quinapril (Lupin); Quinapril (Ranbaxy) ;Accupro.
Clinical Use
Angiotensin converting enzyme inhibitor:
Hypertension
Congestive heart failure
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
Bee venom extract: possible severe anaphylactoid reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Cytotoxics: increased risk of angioedema with everolimus.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Gold: flushing and hypotension with sodium aurothiomalate.
Lithium: reduced excretion (possibility of enhanced lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.
Stoffwechsel
Quniapril is a prodrug which is metabolised in the liver to its active form, quinaprilat, and to minor inactive metabolites.
Quinaprilat is eliminated primarily by renal excretion.

Quinapril Upstream-Materialien And Downstream Produkte

Quinapril Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

85441-61-8, Quinapril Verwandte Suche:

Send Inquriy